1. Home
  2. REGN vs TEL Comparison

REGN vs TEL Comparison

Compare REGN & TEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$730.17

Market Cap

79.3B

Sector

Health Care

ML Signal

HOLD

TEL

TE Connectivity Ltd. New Switzerland Registered Shares

HOLD

Current Price

$241.02

Market Cap

69.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGN
TEL
Founded
1988
1941
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
79.3B
69.6B
IPO Year
1991
2007

Fundamental Metrics

Financial Performance
Metric
REGN
TEL
Price
$730.17
$241.02
Analyst Decision
Buy
Buy
Analyst Count
24
11
Target Price
$799.33
$258.27
AVG Volume (30 Days)
871.9K
1.5M
Earning Date
01-30-2026
01-21-2026
Dividend Yield
0.48%
1.18%
EPS Growth
2.88
N/A
EPS
41.59
6.16
Revenue
$14,247,800,000.00
$17,262,000,000.00
Revenue This Year
$2.08
$12.56
Revenue Next Year
$6.82
$7.47
P/E Ratio
$17.62
$39.13
Revenue Growth
2.89
8.94
52 Week Low
$476.49
$116.30
52 Week High
$821.11
$250.67

Technical Indicators

Market Signals
Indicator
REGN
TEL
Relative Strength Index (RSI) 40.60 62.31
Support Level $743.94 $224.21
Resistance Level $766.64 $243.03
Average True Range (ATR) 20.38 4.68
MACD -8.52 1.23
Stochastic Oscillator 3.37 91.15

Price Performance

Historical Comparison
REGN
TEL

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About TEL TE Connectivity Ltd. New Switzerland Registered Shares

TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.

Share on Social Networks: